Barisic will transition from current role as Chief Financial and Administrative Officer in January 2023
Site Search
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation
With promising new discoveries in the pipeline and advancements we've made in the search for new treatments and a cure, we must continue our work to protect access to adequate, affordable insurance that preserves access to high-quality cystic fibrosis care; and support progress toward new therapies and a cure.
Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF
Robust funding for the National Institutes of Health helps ensure innovation in basic research and a full pipeline of cystic fibrosis therapies. A well-resourced U.S. Food and Drug Administration helps advance therapies that are safe and effective.
In a complex and rapidly changing health care system, we support policies that promote adequate, affordable health coverage so people living with cystic fibrosis can receive the high-quality, specialized care they need to live longer, healthier lives.
Learn more about our Charitable Solicitation Disclosures.